{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06425198",
            "orgStudyIdInfo": {
                "id": "IM027-1009"
            },
            "organization": {
                "fullName": "Bristol-Myers Squibb",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment",
            "officialTitle": "A Phase 1, Multi-center, Open-label Study to Assess the Pharmacokinetics and Safety of BMS-986278 in Healthy Participants and Those With Mild, Moderate and Severe Hepatic Impairment",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-to-assess-drug-levels-and-safety-of-bms-in-healthy-participants-and-participants-with-different-degrees-of-hepatic-impairment"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-23",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-23",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-17",
            "studyFirstSubmitQcDate": "2024-05-17",
            "studyFirstPostDateStruct": {
                "date": "2024-05-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Bristol-Myers Squibb",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to assess the drug levels and safety of BMS-986278 in participants with mild, moderate, and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function."
        },
        "conditionsModule": {
            "conditions": [
                "Hepatic Impairment",
                "Healthy Participants"
            ],
            "keywords": [
                "Healthy Volunteers",
                "Pharmacokinetics",
                "Liver Diseases",
                "Mild, Moderate and Severe Hepatic Impairment",
                "BMS-986278"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 48,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group A: Mild Hepatic Impairment BMS-986278",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986278"
                    ]
                },
                {
                    "label": "Group B: Moderate Hepatic Impairment BMS-986278",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986278"
                    ]
                },
                {
                    "label": "Group C: Severe Hepatic Impairment BMS-986278",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986278"
                    ]
                },
                {
                    "label": "Group D: Normal Hepatic Function BMS-986278",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986278"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BMS-986278",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Group A: Mild Hepatic Impairment BMS-986278",
                        "Group B: Moderate Hepatic Impairment BMS-986278",
                        "Group C: Severe Hepatic Impairment BMS-986278",
                        "Group D: Normal Hepatic Function BMS-986278"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum observed concentration (Cmax)",
                    "timeFrame": "Up to day 9"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]",
                    "timeFrame": "Up to day 9"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]",
                    "timeFrame": "Up to day 9"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence of adverse events (AEs)",
                    "timeFrame": "Up to 62 days"
                },
                {
                    "measure": "Incidence of serious adverse events (SAEs)",
                    "timeFrame": "Up to 62 days"
                },
                {
                    "measure": "Number of participants with physical examination abnormalities",
                    "timeFrame": "Up to 62 days"
                },
                {
                    "measure": "Number of participants with vital sign abnormalities",
                    "timeFrame": "Up to 62 days"
                },
                {
                    "measure": "Number of participants with electrocardiogram (ECG) abnormalities",
                    "timeFrame": "Up to 62 days"
                },
                {
                    "measure": "Number of participants with clinical laboratory abnormalities",
                    "timeFrame": "Up to 62 days"
                },
                {
                    "measure": "Time of maximum observed concentration (Tmax)",
                    "timeFrame": "Up to day 9"
                },
                {
                    "measure": "Terminal elimination half-life (T-HALF)",
                    "timeFrame": "Up to day 9"
                },
                {
                    "measure": "Apparent body clearance (CLT/F)",
                    "timeFrame": "Up to day 9"
                },
                {
                    "measure": "Maximum observed plasma concentration of unbound drug (Cmax_u)",
                    "timeFrame": "Up to day 9"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration of unbound drug [AUC(0-T)_u]",
                    "timeFrame": "Up to day 9"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time 0 extrapolated to infinite time of unbound drug [AUC(INF)_u]",
                    "timeFrame": "Up to day 9"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nAll Participants:\n\n* Must have a body mass index (BMI) between 18 and 40 kg/m\\^2 (inclusive), and body weight \u2265 50 kg.\n\nMild, Moderate, or Severe Hepatic Impairment Participants:\n\n* Mild, moderate, or severe hepatic impairment (HI) or cirrhosis due to chronic hepatic disease and/or prior alcohol use.\n* Mild, moderate, and severe HI participants will be enrolled according to the Child-Pugh classification score.\n\nMatched Healthy Participants:\n\n* Free of any clinically significant disease that would interfere with the study evaluations.\n* Normal hepatic function participants will be enrolled and matched individually with HI participants with respect to age (\u00b1 10 years), weight (\u00b1 20%), sex, and race/ethnicity (Japanese and Chinese participants vs non-Japanese and non-Chinese participants).\n\nExclusion Criteria:\n\nAll Participants:\n\n* History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 7 units for women, or 14 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).\n\nMild, Moderate, or Severe Hepatic Impairment Participants:\n\n* Acute liver disease (eg, caused by an acute infection or drug toxicity).\n* History of initial stage/planned liver transplantation within 6 months of screening or has received a liver transplant.\n\nMatched Healthy Participants:\n\n* Any significant medical condition, or psychiatric illness that would prevent participant from participating in the study.\n* Other protocol-defined inclusion/exclusion criteria apply.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMS Study Connect Contact Center www.BMSStudyConnect.com",
                    "role": "CONTACT",
                    "phone": "855-907-3286",
                    "email": "Clinical.Trials@bms.com"
                },
                {
                    "name": "First line of the email MUST contain NCT # and Site #.",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bristol-Myers Squibb",
                    "affiliation": "Bristol-Myers Squibb",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Panax Clinical Research",
                    "status": "RECRUITING",
                    "city": "Miami Lakes",
                    "state": "Florida",
                    "zip": "33027",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Robert Perry, Site 0001",
                            "role": "CONTACT",
                            "phone": "305-698-4500"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.90871,
                        "lon": -80.30866
                    }
                },
                {
                    "facility": "Orlando Clinical Research Center OCRC",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32809",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Thomas Marbury, Site 0003",
                            "role": "CONTACT",
                            "phone": "407-257-3462"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Elixia",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33618",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Fadi Saba, Site 0002",
                            "role": "CONTACT",
                            "phone": "888-925-9486"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "BMS Clinical Trial Information",
                    "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"
                },
                {
                    "label": "FDA Safety Alerts and Recalls",
                    "url": "http://www.fda.gov/MEDWATCH/safety.htm"
                },
                {
                    "label": "BMS Clinical Trial Patient Recruiting",
                    "url": "https://www.bmsstudyconnect.com/content/studyconnect/us/en/clinical-trials/NCT06425198.html"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.\n\nAdditional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and research/disclosurecommitment.html"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "asFound": "Hepatic Impairment",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}